Ads
related to: list of platelet inhibitors for prostate cancer- Educational Brochures
Get Resources Now For
APC Treatment
- Safety & Efficacy Video
Watch A Video To Learn
More About This Treatment Option.
- Coverage for Rx Treatment
Learn About Coverage
In Your Area
- Patient Support Program
Support to Help Your Patients
Get Started and Stay on Track
- Access Patient Resources
Download Dosing Card &
Support Program Brochure
- Prescribing Information
Advanced Prostate Cancer Treatment
View Prescribing Information
- Educational Brochures
Search results
Results From The WOW.Com Content Network
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Dipyridamole inhibits platelet phosphodiesterase, causing an increase in cyclic AMP with potentiation of the action of PGI 2 – opposes actions of TXA 2 Epoprostenol is a prostacyclin that is used to inhibit platelet aggregation during renal dialysis (with or without heparin) and is also used in primary pulmonary hypertension.
Prostacyclin, which has a half-life of 42 seconds, [9] is broken down into 6-keto-PGF 1, which is a much weaker vasodilator.A way to stabilize prostacyclin in its active form, especially during drug delivery, is to prepare prostacyclin in alkaline buffer.
Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).
Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug [5] for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. [5]
Ad
related to: list of platelet inhibitors for prostate cancer